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790 Original ResearchBACKGROUND: Clinical characteristics of the international population with severe asthma are
unknown. Intercountry comparisons are hindered by variable data collection within regional
and national severe asthma registries. We aimed to describe demographic and clinical
characteristics of patients treated in severe asthma services in the United States, Europe, and
the Asia-Pacific region.
METHODS: The International Severe Asthma Registry retrospectively and prospectively
collected data in patients with severe asthma ($ 18 years old), receiving Global Initiative for
Asthma (GINA) Step 5 treatment or with severe asthma remaining uncontrolled at GINA
Step 4. Baseline demographic and clinical data were collected from the United States, United
Kingdom, South Korea, Italy, and the Severe Asthma Web-based Database registry (including
Australia, Singapore, and New Zealand) from December 2014 to December 2017.
RESULTS:We included 4,990 patients.Mean (SD) age was 55.0 (15.9) years, andmean (SD) age at
asthma onset was 30.7 (17.7) years. Patients were predominantly female (59.3%) and white
(72.6%), had never smoked (60.5%), and were overweight or obese (70.4%); 34.9% were at GINA
Step 5; and 57.2% had poorly controlled disease. A total of 51.1% of patients were receiving
regular intermittent oral corticosteroids, and 25.4% were receiving biologics (72.6% for those at
GINA Step 5). Mean (SD) exacerbation rate was 1.7 (2.7) per year. Intercountry variation was
observed in clinical characteristics, prescribed treatments, and biomarker profiles.
CONCLUSIONS: Using a common data set and definitions, this study describes severe asthma
characteristics of a large patient cohort included in multiple severe asthma registries and
identifies country differences. Whether these are related to underlying epidemiological fac-
tors, environmental factors, phenotypes, asthma management systems, treatment access, and/
or cultural factors requires further study. CHEST 2020; 157(4):790-804KEY WORDS: biologics; comorbidity; eosinophils; FENO; IgEsthma-COPD overlap; AR = allergic
hil count; CRS = chronic rhinosinusitis;
ic oxide; GINA = Global Initiative for
resource use; ISAR = International Se-
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Severe asthma is defined as “asthma which requires
treatment with high dose inhaled corticosteroids (ICS)
plus a second controller (and/or systemic
corticosteroids) to prevent it from becoming
‘uncontrolled,’ or which remains ‘uncontrolled’ despite
this therapy.”1 Other definitions include lack of control
with use of maximal optimized therapy and treatment of
contributory factors.2 Severe asthma is thought to affect
approximately 5% to 10% of the total population with
asthma,1 although a large prevalence range (1.8%-38%)
has been reported.3 Severe asthma is associated with
significant morbidity4 and mortality5-7 and treatment,8
psychological,9 and socioeconomic10 burdens, with
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severe asthma can be tenfold higher than that of mild
disease, accounting for more than 60% of asthma-related
health-care costs.13 Many patients are unable to
maintain full-time employment,14 with a high degree of
presenteeism and absenteeism reported.15
The World Health Organization emphasizes asthma’s
contribution to the global symptom and economic burden
and calls for “better surveillance to map the magnitude
of chronic respiratory diseases and analyze their
determinants.and tomonitor future trends.”16TheGlobal
Asthma Report stresses the need for asthma monitoring to
be ongoing, appealing for countries to conduct asthma
surveillance, with regular investigation of trends.17
Regional and national severe asthma registries already
exist and collect valuable country-specific data.18-25
However, they typically contain relatively small
numbers and tend to target specific subsets of severe
asthma. Combining data is delayed until individual
registry data are published and is hindered by different
definitions used and variables collected. The
International Severe Asthma Registry (ISAR; http://
isaregistries.org/), the first worldwide adult severe
asthma registry, overcomes some of these
limitations26,27 and answers the World Health
Organization and Global Asthma Report calls to
action.16,17 In partnership with national and regional
registries, ISAR collects patient-level, pseudonymous,
longitudinal, real-life, standardized, high-quality data,
using a set of core variables, from countries across the
world for ethically approved research purposes.27 ISAR
contains data in a greater breadth of patients within the
severe asthma definition and has sufficient power to
answer important clinical questions. The aim of this
article is to describe the demographic and clinical
characteristics of patients with severe asthma treated in
secondary and tertiary asthma centers in the United
States, Europe, and the Asia-Pacific region and to study
intercountry differences.
Materials and Methods
Patients
Because this is a historical, registry study, patients were not recruited
but rather included into ISAR from other existing and newly created
registries. ISAR essentially acts as a data custodian. Participating
countries retain ownership of their own data but have agreed to
provide access to, and share anonymous patient-level data with,
ISAR for approved research purposes. Patient data are transferred to
the ISAR database at regular intervals. Details of how data are
extracted from national registries to ISAR are provided in the online791
supplement (e-Appendix 1). A country lead has been identified for
each registry and is responsible for overseeing data collection,
including combining data from any satellite sites, before making the
countrywide data available to ISAR. This approach, in effect, allows
for the creation of a locally hosted central registry for the country’s
combined data, which can be used to enhance local- and
international-level research. Full details about asthma diagnostic
criteria and the definition of severe asthma for each of these
registries are provided in the online supplement (e-Tables 1, 2).
Patients in ISAR are 18 years or older, received treatment at Global
Initiative for Asthma (GINA) Step 5 or had uncontrolled asthma at
GINA Step 4 (at inclusion),1,28 and provided consent for their data
to be included (except in the United States, where consent was not
required because data were deidentified). Smokers and those with
asthma-COPD overlap (ACO) were not excluded. ISAR is currently
developing a protocol to identify patients with ACO within its severe
asthma cohort. These eligibility criteria were chosen to reflect patients
with severe asthma in the real-world setting and to broaden the scope
to include patients with uncontrolled moderate to severe asthma.
Data Collected
Aggregated baseline demographic and clinical data for prespecified
analyses were transferred to ISAR from secondary and tertiary severe
asthma centers in the United Kingdom, Italy, South Korea, and
Australia. Patient-level data were contributed by the United States.
Patients in the US registry were identified by meeting the ISAR
eligibility criteria on the basis of their diagnostic labeling
medications to assess GINA Step 4 or Step 5 treatment and asthma
control test score and/or prebronchodilator FEV1 < 80% predicted
to ascertain asthma control status from their retrospective electronic
medical health records. Data were collected from the following
registries from December 2014 to December 30, 2017: National
Jewish Health Electronic Medical Record Severe Asthma Cohort
(United States, from all regions [predominantly Colorado and
Wyoming] and a small proportion from other countries); the UK
Severe Asthma Network and National Registry (four sites)19; the
Korean Academy of Asthma, Allergy and Clinical Immunology
registry (15 sites)25; the Severe Asthma Network Italy (61 sites)24;
and the Australasian Severe Asthma Network’s registry (ie, Severe
Asthma Web-based Database [SAWD], including patient data from
Australia, Singapore, and New Zealand: 23 sites).20
ISAR captures 95 core variables agreed by means of Delphi
consensus.27 Those presented in this article are summarized in
e-Tables 3 and 4. The number of exacerbations was defined as the
number requiring rescue systemic corticosteroids in the past
12 months. The United States used duration of OCS as a proxy for
exacerbation (assuming one OCS course lasts $ 7 days), in line with
GINA 2018 recommendations and previously published research and792 Original Researchbased on discussion with the site investigator.28,29 A retrospective
analysis of National Jewish Health prescriptions showed that most
prednisolone prescriptions were for at least 7 days for short-term
use. The number of hospitalization and ED admissions for asthma
was the number in the past 12 months. The number of times
invasive ventilation was used was the number of episodes before data
extraction. Comorbidity was based on a formal diagnosis or reliably
inferred from relevant prescription data. For the United States,
comorbidity data were captured using International Classification of
Diseases, Tenth Revision codes for active diagnosis of comorbidity.
Prescription data were used as a supplement to identify the
comorbidity status of allergic rhinitis (AR) and eczema because their
active diagnosis was underreported in the electronic medical records
data. This finding was confirmed by the site lead (E. W.) and
additional practitioners at the clinic. In addition to tracking regular
OCS use (defined as $ 90 days of OCS use in a year), to capture
risk for systemic corticosteroid adverse effects, intermittent OCS use
was defined as the prescription for repeated OCS use and/or $ 2
exacerbations in a 1-year period.30 Asthma control was categorized
as controlled, partly controlled, or uncontrolled according to GINA
criteria,28 determined using the Asthma Control Test questionnaire31
or the Asthma Control Questionnaire.32
Ethics and Governance
This study was designed, implemented, and reported in accordance
with the European Network Centres for Pharmacoepidemiology and
Pharmacovigilance (European Medicines Agency 2014; EUPAS25489;
http://www.encepp.eu/encepp/viewResource.htm?id=27888) and
performed in compliance with all applicable local and international
laws and regulations. Governance was provided by the Anonymised
Data Ethics Protocols and Transparency committee (protocol 2249).
All registries participating in ISAR received ethical approval in their
own countries and obtained regulatory agreement to provide
deidentified data to ISAR in compliance with country-specific
international data transfer laws and legislation and their relevant
ethical boards and organizations. All patient-level data extracted and
transferred from the United States were deidentified and entered into
the research database as anonymized patient identification numbers.Statistical Analysis
Data were assessed using Stata version 14 (StataCorp) or SAS version
9.4 or 9.5 (SAS Institute) according to a predefined data analysis plan
to minimize bias. Descriptive statistics were reported as categorical
variables for all variables for the overall and country-specific patient
populations. Health-care resource use (HCRU), IgE count, blood
eosinophil count (BEC), and comorbidities also were stratified by
severe asthma status and sex for the overall population.Results
Demographic Characteristics
The study included 4,990 eligible patients with individual-
level data from the United States (n¼ 3,286) and aggregate
data from the United Kingdom (n ¼ 696), South Korea
(n ¼ 439), Italy (n ¼ 310), and the SAWD registry (n ¼
259). Mean (SD) age was 55 (15.9) years, and mean (SD)
age at asthma onset was 30.7 (17.7) years. Patients were
predominantly female (59.3%), were aged 55 to 79 years
(52.1%), were white (72.6%), had never smoked (60.5%),and were overweight or obese (70.4%); 34.9% were at GINA
Step 5; and 57.2% had poorly controlled disease. A total of
51.1% of patients were receiving regular intermittent OCS,
and 25.4% were receiving biologics (72.6% for those at
GINA Step 5). Mean (SD) exacerbation rate was 1.7 (2.7)
per year (Table 1). South Korea had the oldest patients, the
lowest prevalence of patients who were overweight or obese,
and the highest prevalence of current smokers (12.1%).
Approximately one-third of individuals from the SAWD
registry (30.0%), South Korea (33.9%), and the United
States (36.8%) were exsmokers (e-Table 5).[ 1 5 7 # 4 CHES T A P R I L 2 0 2 0 ]
TABLE 1 ] Demographic Characteristics of All Patients
in the ISAR Database
Characteristic Data
Sex, No. (%) (n ¼ 4,986)
Female 2,957 (59.3)
Male 2,029 (40.7)
Age, y (n ¼ 4,967)
Mean (SD) 55.0 (15.9)
18-34, No. (%) 658 (13.2)
35-54, No. (%) 1,510 (30.4)
55-79, No. (%) 2,588 (52.1)
$ 80, No. (%) 211 (4.2)
Ethnicity, No. (%) (n ¼ 4,912)
White 3,568 (72.6)
Asian 589 (12.0)
African 263 (5.4)
Mixed 31 (0.6)
Other 130 (2.6)
Unknown 331 (6.7)
BMI, No. (%), kg/m2 (n ¼ 4,901)
Underweight (< 18.5) 105 (2.1)
Normal ($ 18.5 to < 25) 1,345 (27.4)
Overweight ($ 25 to < 30) 1,531 (31.2)
Obese ($ 30) 1,920 (39.2)
Smoking status, No. (%) (n ¼ 4,947)
Current smoker 294 (5.9)
Exsmoker 1,656 (33.5)
Never smoked 2,997 (60.6)
The number refers to the total number of patients with nonmissing data.
Percentages may not total 100% because of rounding. ISAR ¼ Internal
Severe Asthma Registry.
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Severity and Lung Function: Most patients had
uncontrolled asthma at GINA Step 4 (Fig 1). There was
a higher proportion of women both among patients with
uncontrolled asthma at GINA Step 4 (59.3%) and
among patients with asthma at GINA Step 5 (59.4%).
Patients from the United Kingdom and Italy tended
to have more severe disease, and those from the
United States and South Korea tended to have the least
severe compared with patients in other countries (Fig 1).
Percent predicted FEV1 and FVC values appeared to be
independent of severity, showed some intercountry
variability, and showed little postbronchodilator
improvement (Table 2). The mean (SD)
postbronchodilator FEV1/FVC was 0.69 ( 0.13) for
patients at GINA Step 5 and 0.71 (0.13) for those with
uncontrolled asthma at GINA Step 4 (Table 2),
indicating a substantial presence of fixed airway
obstruction. The percentages of patients with FEV1/
FVC < 0.7 were 43% and 47% for GINA Step 4 and Step
5, respectively. Bronchoconstriction was considered
irreversible33 for those in both severity groups and
irrespective of smoking history. Some intercountry
variability was noted (Table 3).33,34 These findings not
only justify the ISAR inclusion criteria for severe asthma
but also ratify the definition of severe asthma as outlined
by the European Respiratory Society and American
Thoracic Society.1 Incidentally, those with low or limited
reversibility are routinely excluded from asthma clinical
trials. The inclusive nature of ISAR and broad definition34.9
23.3
81.8
22.3
68.1
37.4
GINA Step 5
A (n = 3,286) UK (n = 696)
n = 310) SAWD (n = 259)
hma Registry population and by country. GINA ¼ Global Initiative for
outh Korea; UK ¼ United Kingdom; USA ¼ United States.
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TABLE 2 ] Lung Function in Patients With Uncontrolled Asthma at GINA Step 4 or Asthma at GINA Step 5 Included
in ISAR and According to Country and Registry
Country or
Registry
Uncontrolled Asthma at GINA Step 4
Prebronchodilator Postbronchodilator
FEV1 (SD) FVC (SD) FEV1/FVC (SD) FEV1 (SD) FVC (SD) FEV1/FVC (SD)
All 71.9 (15.3)
(n ¼ 2,801)a
78.7 (14.9)
(n ¼ 2,936)
0.69 (0.12)
(n ¼ 2,633)
75.6 (16.0)
(n ¼ 2,104)
81.8 (14.6)
(n ¼ 2,501)
0.71 (0.13)
(n ¼ 1,755)
United States 72.3 (13.7)
(n ¼ 2,244)
78.2 (14.1)
(n ¼ 2,382)
0.70 (0.11)
(n ¼ 2,512)
75.8 (14.1)
(n ¼ 1,591)
81.4 (13.6)
(n ¼ 1,639)
0.71 (0.13)
(n ¼ 1,732)
United
Kingdom
72.5 (22.3)
(n ¼ 117)
85.2 (17.8)
(n ¼ 114)
.b 77.5 (22.5)
(n ¼ 73)
91.5 (18.1)
(n ¼ 71)
.b
South Korea 68.1 (20.1)
(n ¼ 341)
76.7 (18.0)
(n ¼ 341)
0.6 (0.16)
(n ¼ 12)
73.8 (21.1)
(n ¼ 341)
81.9 (18.2)
(n ¼ 341)
0.62 (0.17)
(n ¼ 12)
Italy 74.2 (20.5)
(n ¼ 99)
91.5 (18.8)
(n ¼ 99)
0.65 (0.11)
(n ¼ 109)
77.1 (19.1)
(n ¼ 99)
.c 0.59 (0.14)
(n ¼ 11)
GINA Step 5
All 70.4 (19.0)
(n ¼ 1,437)a
82.5 (17.3)
(n ¼ 1,484)
0.68 (0.12)
(n ¼ 1,045)
76.2 (19.2)
(n ¼ 975)
84.5 (17.3)
(n ¼ 775)
0.69 (0.13)
(n ¼ 530)
United States 74.9 (15.8)
(n ¼ 625)
80.1 (15.3)
(n ¼ 688)
0.69 (0.11)
(n ¼ 740)
75.5 (15.6)
(n ¼ 390)
82.1 (14.2)
(n ¼ 413)
0.69 (0.13)
(n ¼ 445)
United
Kingdom
65.2 (22.0)
(n ¼ 503)
84.5 (20.4)
(n ¼ 487)
.b 71.1 (21.9)
(n ¼ 276)
89.9 (20.5)
(n ¼ 264)
.b
South Korea 68.0 (20.7)
(n ¼ 98)
77.5 (19.0)
(n ¼ 98)
0.60 (0.13)
(n ¼ 8)
72.1 (21.4)
(n ¼ 98)
80.4 (19.8)
(n ¼ 98)
0.63 (0.15)
(n ¼ 8)
Italy 70.7 (18.8)
(n ¼ 211)
88.3 (18.4)
(n ¼ 211)
0.66 (0.13)
(n ¼ 297)
86.0 (20.5)
(n ¼ 211)
.c 0.68 (0.14)
(n ¼ 77)
FEV1 and FVC data are presented as mean (SD) % predicted. The % predicted data are based on aggregate-level data from the United Kingdom, United States,
South Korea, and Italy; aggregate data for % predicted lung function were not available for patients in the SAWD registry. FEV1/FVC is derived from patient-level
lung function data from the United States, South Korea, and Italy. GINA ¼ Global Initiative for Asthma. See Table 1 legend for expansion of other abbreviation.
aThe number refers to the total number of patients with nonmissing data.
bPatient-level data were used to compute the FEV1/FVC ratio; these data were not available for the United Kingdom but were available for 12 and eight
patients (GINA Steps 4 and 5, respectively) from South Korea.
cData were not available for postbronchodilator % predicted FVC for Italy.
TABLE 3 ] Bronchodilator Reversibility (%) as a Function of Asthma Severity and Smoking Status for All Patients
Included in ISAR and According to Country and Registry
Country
Uncontrolled at GINA Step 4 GINA Step 5
Smokers Nonsmokers Smokers Nonsmokers
ERS definition (change from % predicted FEV1, threshold > 9%)
33
All (n ¼ 2,120)a 6.9% (6.9) 6.7% (7.8) 7.6% (8.1) 7.0% (8.6)
United States (n ¼ 1,849) 7.0% (6.9) 6.6% (6.9) 7.0% (7.9) 6.5% (7.8)
South Korea (n ¼ 20) 6.2% (6.9) 5.0% (4.9) 4.1% (3.1) 9.0% (5.1)
Italy (n ¼ 251) 7.5% (7.0) 9.0% (17.5) 9.9% (9.0) 7.6% (9.8)
ATS definition (change from initial FEV1 (%), threshold > 12%)
34
All (n ¼ 2,238)a 12.0% (16.3) 8.2% (8.0) 13.2% (14.8) 12.0% (17.7)
United States (n ¼ 1,967) 12.0% (16.4) 11.9% (17.9) 13.0% (15.4) 11.9% (17.4)
South Korea (n ¼ 20) 10.1% (11.4) 13.1% (22.6) 6.9% (5.7) 11.4% (7.0)
Italy (n ¼ 251) 10.7% (9.2) 13.1% (22.6) 14.8% (13.2) 12.1% (18.3)
Bronchodilator reversibility (% change in lung function) data are presented as mean (SD) bronchodilator reversibility according to ERS and ATS definitions.
ATS ¼ American Thoracic Society; ERS ¼ European Respiratory Society. See Tables 1 and 2 legends for expansion of other abbreviations.
aThe number represents the total number of patients with nonmissing data and includes patients at both GINA Step 4 and GINA Step 5. Patient-level data
from the United States and Italy were used to compute bronchodilator reversibility (% change in lung function); these data were not available for the United
Kingdom but were available for 20 patients from South Korea.
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TABLE 4 ] Demographic and Clinical Characteristics for All Patients Included in ISAR and According to Country and Registry
Patients With Uncontrolled Asthma at GINA Step 4 or at GINA Step 5 Patients at GINA Step 5 Onlya
Country or
Registry
Age, Mean
(SD), y
Overweight
or obese, %
(95% CI)
Age at
Onset, Mean
(SD), y
Exacerbations
per Year,
Mean (SD)
Receiving
Repeated
Intermittent
OCS, %
(95% CI)
Receiving
Regular OCS, %
(95% CI)
Receiving
Biologics
(Anti-IgE or
Anti-IL-5), %
(95% CI)
Receiving
Regular OCS,
% (95% CI)
Receiving
Biologics
(Anti-IgE or
Anti-IL-5), %
(95% CI)
All
(N ¼ 4,990)
55.0 (15.9) 70.4
(69.1-71.7)
30.7 (17.7) 1.7 (2.7) 51.1
(49.8-52.5)
30.1
(24.5-35.7)
25.4
(24.2-26.6)
48.8
(38.8-58.7)
72.6
(63.8-81.5)
United States
(n ¼ 3,286)
55.5 (16.7) 74.2
(70.0-78.3)
.b 0.8 (1.6)c 26.8
(25.3-28.4)
23.3
(21.8-24.7)
16.2
(15.0-17.5)
20.4
(17.5-23.2)
69.8
(60.7-78.9)
United
Kingdom
(n ¼ 696)
48.3 (14.1) 78.2
(74.3-82.1)
25.4 (18.7) 5.0 (4.0) 100.0 (0-0) 59.6
(56.0-63.3)
67.3
(63.8-70.8)
72.9
(69.3-76.6)
82.4
(74.8-89.9)
South Korea
(n ¼ 439)
62.4 (14.1) 35.1
(30.6-39.6)
41.0 (17.1) 1.1 (1.5) 48.3
(43.6-53.0)
20.7
(16.9-24.5)
1.4
(0.3-2.4)
92.9
(87.8-98.0)
6.1
(1.4-10.9)
Italy
(n ¼ 310)
54.5 (13.8) 54.6
(49.9-59.3)
34.4 (17.1) 3.7 (7.2) 92.3
(89.3-95.2)
63.1
(56.5-69.1)
69.3
(64.2-74.5)
61.4
(54.9-68.0)
100.0
(0-0)
SAWD
(n ¼ 259)d
55.1 (15.3) 80.6
(76.9-84.3)
22.7 (17.1) 3.3 (2.9) 85.3
(81.0-89.6)
24.7
(19.5-30.0)
17.0
(12.4-21.6)
66
(56.6-75.4)
45.4
(35.5-55.2)
Exacerbations are defined as requiring rescue steroids in the past year or are defined according to OCS duration (assuming one course lasts $ 7 days). Regular OCS is defined as a prescription for $ 90 days of OCS
exposure in the observation year. Intermittent OCS use is defined as a prescription for repeated OCS use and/or $ 2 exacerbations (treated with OCS). OCS ¼ oral corticosteroid; SAWD ¼ Severe Asthma Web-based
Database. See Tables 1 and 2 legends for expansion of other abbreviations.
aGINA Step 5: All (n ¼ 1,740), United States (n ¼ 765), United Kingdom (n ¼ 569), South Korea (n ¼ 98), Italy (n ¼ 211), SAWD (n ¼ 97).
bUS data were not available for age at asthma onset.
cThe duration of OCS exposure was used as a proxy for asthma exacerbation assuming one course lasts $ 7 days.
dAustralia (n ¼ 225), Singapore (n ¼ 16), and New Zealand (n ¼ 18).
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of severe asthma means that for the first time this
population can be properly studied and characterized.
Age at Onset: The mean (SD) age at onset was 30.7
(17.7) years; 77.5% of patients developed asthma after
the age of 12 years and 34.4% developed it after the age
of 40 years. Patients from the United Kingdom and the
SAWD registry developed asthma slightly earlier than
this, and those from South Korea and Italy slightly later
(Table 4, e-Table 6).
Asthma Control, Exacerbations, and HCRU: Figure 2
shows the proportion of patients with well-controlled,
poorly controlled, and uncontrolled asthma31,32 in the
total population and also in each of the individual
registries. At entry to their national registry, 57.2% of
patients had poorly controlled asthma; this percentage
was highest in the United Kingdom and the SAWD
registry and lowest in Italy and South Korea. The
proportions of patients with well-controlled, partly
controlled, and uncontrolled asthma were similar in the
GINA Step 4 (uncontrolled asthma at entry) and GINA
Step 5 groups (e-Fig 1). The mean (SD) number of
exacerbations (past 12 months) was 1.7 (2.7). One-
quarter of patients reported $ 4 exacerbations (Fig 3).
The number of exacerbations was driven by severity,
with most patients with uncontrolled asthma at GINA
Step 4 (at inclusion) reporting 0 exacerbations (71.1%),
whereas 42.5% of patients at GINA Step 5 reported $ 4
exacerbations. The mean number of exacerbations wasP
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Figure 2 – Proportion of patients with poorly controlled, not well-controlled
Registry population and by country. Control is defined according to Asthma
Control Test: well controlled, 20 to 25; not well controlled, 16 to 20; and ver
controlled, 0 to 0.75; gray zone, 0.75 to 1.5; and poorly controlled, > 1.5.32
796 Original Researchlowest in the United States and South Korea and highest
in the United Kingdom (Fig 3, Table 4). HCRU was high
overall but highest in the United Kingdom and lowest in
South Korea (Fig 4), and was slightly higher for patients
at GINA Step 5 (e-Fig 2, e-Table 6).
IgE Concentration: One-half of the patient population
with severe asthma had low IgE concentrations (< 150
IU/mL) (Fig 5A). The IgE profile varied according to
severity. More patients with uncontrolled asthma at
GINA Step 4 (vs GINA Step 5) had low IgE
concentrations (59.4% vs 43.7%). Conversely, more
patients at GINA Step 5 (vs those with uncontrolled
asthma at GINA Step 4) had high IgE concentrations
(30.6% vs 23.3%). More women had low IgE
concentrations, and more men had high IgE
concentrations, irrespective of severity. Most patients
from the United States had low IgE serum concentrations,
whereas patients from the United Kingdom, South
Korea, and the SAWD registry showed a more even
split between low vs intermediate or high IgE
concentrations. An even distribution of patients across
the IgE concentration categories was noted in Italy
(Fig 5A).
BEC: For BEC, 48.5% of patients had a BEC > 0.3 109/
L. Most patients in the United States, South Korea, and
the SAWD registry had a BEC # 0.3 109/L, whereas
most patients from the United Kingdom and Italy had a
BEC > 0.3 109/L (Fig 5B)..6
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Control Test or Asthma Control Questionnaire categorizations. Asthma
y poorly controlled, 5 to 15.31 Asthma Control Questionnaire: well
See Figure 1 legend for expansion of abbreviations.
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Figure 3 – Proportion of patients with 0, 1, 2, 3, and$ 4 asthma exacerbations in the past 12 months in the total International Severe Asthma Registry
population and by country. An exacerbation was defined as a symptom episode requiring rescue steroids in the past year. *In the United States,
duration of oral corticosteroid (OCS) was used as a proxy for exacerbation (assuming one OCS course lasts$ 7 days). See Figure 1 legend for expansion
of other abbreviations.Fractional Exhaled Nitric Oxide: Overall, 43.1% of
patients with severe asthma had fractional exhaled nitric
oxide (FENO) concentrations < 25 parts per billion (ppb),
and 56.9% had a concentration $ 25 ppb. In the United
States, a similar proportion of patients had FENO
concentrations< 25 ppb and$ 25 ppb.Most patients from
the United Kingdom, South Korea, and Italy had FENO
concentrations$ 25 ppb, whereas most patients in the
SAWDregistry had FENO concentrations< 25 ppb (Fig 5C).P
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Figure 4 – Health-care resource use (HCRU) in the total International Seve
available for the United States. See Figure 1 legend for expansion of other a
chestjournal.orgComorbidities: AR was the predominant comorbidity
(49.4%) in the total population, followed by chronic
rhinosinusitis (CRS; 21.4%), eczema (9.6%), and nasal
polyps (NPs; 7.3%). AR was the predominant comorbidity
in all countries. The United States had the highest
prevalence of comorbid CRS (26.8%), the SAWD
registry had the highest eczema prevalence (20.5%), and
Italy had the highest NP prevalence (22.3%) (e-Fig 3, e-
Table 6).13.9
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Treatment: Across all patients (ie, those at GINA Step 4
or Step 5), 51.1% were receiving repeated intermittent
OCS. Those from the United Kingdom, Italy, and the
SAWD registry had the highest intermittent OCS use,
and the United States had the lowest (Table 4).
All patients with uncontrolled asthma atGINAStep 4were
receiving inhaled corticosteroid and long-acting b2-
agonist therapy. The most common add-on to inhaled
corticosteroid and long-acting b2-agonist was leukotriene
receptor antagonist (LTRA), followed by long-acting
muscarinic receptor antagonist (LAMA) and theophyllineP
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Figure 6 – Medication regimen for (A) those with uncontrolled asthma at GI
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chestjournal.org(Fig 6A). The same pattern was noted in the US and UK
registries. However, in South Korea, theophylline was used
more commonly than was LAMA; in Italy, LAMA was
used more commonly than was LTRA. The United
Kingdom had the highest proportion of patients receiving
add-on LAMA. Add-on therapy was used sparingly in the
United States for patients with uncontrolled asthma at
GINA Step 4 (at baseline) (Fig 6A).
Add-on regular OCS was used by almost one-half of
the patients at GINA Step 5, anti-IgE and anti-IL-5
were each used by approximately one-third of patients,.2
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and macrolides were prescribed for a minority. A wide
range of intercountry variability was noted for regular
OCS use (Fig 6B). Overall, 72.6% of patients with
severe asthma at GINA Step 5 were receiving
therapeutic monoclonal antibody therapy (ie, biologics),
with notably high rates in Italy and the United
Kingdom and a relatively low rate of use in South
Korea (Fig 6B, Table 4). In Italy, the predominant
biologic was anti-IgE, but in the United Kingdom it
was anti-IL-5. The United States differed from other
countries in having a fairly even split between anti-IgE
and anti-IL-5 and also the highest proportion of
patients receiving macrolides (Fig 6B).
Discussion
The international population with severe asthma is
predominantly female, overweight or obese,
nonsmoking, and in the 55- to 79-year age range. These
patients experience 1.7 exacerbations per year on
average, have poorly or not well-controlled asthma in
the majority of cases, a low FEV1/FVC ratio, limited
reversibility, and high HCRU. AR is the predominant
comorbid disease. There is a fairly even proportion of
patients with a low vs an intermediate or high serum IgE
concentration and BEC. Most patients have a high FENO
concentration. Asthma treatment is severity specific.
Approximately 30% of patients are receiving regular
OCS therapy, more than 50% are receiving
OCS intermittently, and approximately three-quarters
of patients with most severe disease are receiving
biologics.
There is substantial interregistry heterogeneity in the
clinical characteristics of patients treated within severe
asthma services. More work is required to explain many
of these intercountry differences definitively. We
hypothesize that some of these differences may be
indicative of variations in cultural and epidemiological
patterns, as well as environmental pressures. Other
differences could reflect country-specific system issues
(eg, differences in patient journey to severe asthma
centers, selection bias, treatment landscape). Some
differences may be explained by intrinsic differences in
the asthma phenotype. ISAR has prioritized numerous
research projects to help answer these outstanding
questions such as investigating the effect of race,
ethnicity, and socioeconomic status on asthma
outcomes, assessing variability in biologic access and use
(both within and between countries), and comparing
OCS use patterns around the world (http://isaregistries.
org/isar-research-updates/).800 Original ResearchSouth Korea had the oldest patients, likely the result of
its aging population,35 and it has yet to experience the
asthma epidemic seen in many Western countries in the
past decades.36 It has also the lowest prevalence of
patients who were overweight or obese, perhaps because
of the beneficial effect of South Korean traditional
diets.37 The high prevalence of current smokers in South
Korea is in keeping with this older population, who
often have ACO,38 and is supported further by the
generally poorer lung function and less reversibility
noted for these patients. The relatively late onset of
asthma in South Korea may be linked to recent
economic development there, and the subsequent
spike in air pollution, associated with an increase in
hospital admissions for asthma.39 Conversely, the
relatively early age of onset of asthma in the United
Kingdom and the SAWD registry may be a
consequence of the epidemic of childhood asthma first
described in the second one-half of the 20th century.40
Age of onset could have implications for response to
biologic therapy; patients with adult onset tend to
respond better to anti-IL-5 or anti-IL-5 receptor, and
those with younger onset tend to respond better to anti-
IgE.2,41
Other intercountry differences noted could be the
result of broad system differences. High numbers of
patients at GINA Step 5 in the United Kingdom and
Italy may occur because patients come from tertiary
asthma centers (with strict referral criteria), so they
naturally have the most severe disease. The high
numbers with well-controlled asthma in Italy and the
low numbers in the United Kingdom and the SAWD
registry most likely are because in Italy patients are
generally follow-up patients receiving biologic therapy,
whereas those from the United Kingdom and the
SAWD registry are generally patients at their first visit,
before biologic use. These factors also help to explain
the high exacerbation rate and HCRU in the United
Kingdom, coupled with the fact that at least four
exacerbations per year is required for biologic
prescription in the United Kingdom.42,43 In contrast,
the high proportion of patients with well-controlled
asthma in South Korea most likely reflects the
rapid access to specialist care, which, along with the
low cost of medications, may explain the low HCRU
there.
The low exacerbation rate noted in the United States is
most likely artificial because exacerbation data were not
captured directly but rather by proxy and conservatively
via OCS use. This is because exacerbations are rarely[ 1 5 7 # 4 CHES T A P R I L 2 0 2 0 ]
coded in the US registry but rather added in the free-text
box. Future work to capture this free-text information,
as well as comorbidity information, is ongoing and will
be provided in future analyses. In the interim, these data
provide a useful benchmark to assess whether proxy
OCS is a good or bad indicator of exacerbation rate.
Definition overlap may account for the high prevalence
of CRS (vs AR) in the United States, whereas routine
nasal examination of patients in Italy may explain the
high prevalence of NPs noted there. The high prevalence
of eczema in the SAWD registry may be accounted for
by a selection bias toward atopy, a requirement for
omalizumab therapy.
Intercountry differences in treatment strategies also were
noted. The high OCS and biologic use in both the
United Kingdom and Italy may be severity driven.
Biologic treatment patterns also differed among these
countries, with Italy having high use of anti-IgE, the
United Kingdom having high use of anti-IL-5, and the
United States exhibiting an even split between anti-IgE
and anti-IL-5. These different patterns probably reflect
biologic availability or perhaps point to phenotypic
differences. The high prevalence of LAMA and LTRA
add-on therapy noted in the United Kingdom aligns
with British Thoracic Society guideline-directed care for
GINA Step 444 and is in keeping with treatment at
primary care. In South Korea, high regular OCS use (for
GINA Step 5) and add-on theophylline and LTRA use
(for GINA Step 4) also were noted, but here the drivers
may be different (eg, patient preference for oral
therapies,45 availability and reimbursement for these
medications). Biologics are not reimbursed in South
Korea and rarely used.
This first ISAR data set also facilitates categorization and
comparison of asthma biomarker phenotypes across
countries. The United Kingdom and Italy appear to have
a predominance of helper T cell (Th2)-high, eosinophilic
asthma, evidenced by high FENO and BEC.2,46,47 The
earlier onset of asthma in the United Kingdom, could
indicate a predominance of allergic asthma, whereas the
later asthma onset, and high prevalence of NPs in Italy
suggest the predominance of a nonallergic phenotype.48
Although baseline IgE levels may not predict the
likelihood of response to biologics,49 the higher BEC
noted in both the United Kingdom and Italy predict a
better response, both to anti-IgE50,51 and to anti-IL-5
and anti-IL-5 receptor.52 High exacerbation rates per
year noted in both countries and the presence of NPs inchestjournal.orgItaly are also factors that may predict a good response to
anti-IL-5 therapy.2 In contrast, the lower BEC and low
FENO biomarker profile noted for the SAWD registry is
more indicative of a population predominantly with
noneosinophilic, Th2-low asthma, whereas the
profiles observed in the United States and South Korea
registries are more ambiguous and could suggest a
split of Th2-high and Th2-low asthma phenotypes
(e-Table 6).
Merging data from preexisting registries brought its own
challenges, including intercountry variability in the type
of patients included in registries and standardization of
variable definitions, as well as use of retrospective data.
Although there was a bias toward white patients in this
first ISAR data set, a much broader ethnic diversity will
be contained in future data sets as ISAR continues to
expand into Asia, Africa, and South America. A strength
of this study is its size and the fact that data collected in
registries are more heterogeneous than those collected in
randomized controlled trials and are more
representative of patients in real life.53 Use of patient-
level data also provides the opportunity to conduct
biostatistical multivariate analyses, track patient
progress longitudinally, and analyze response to
treatment and changes in medical management. It is
important to have both baseline and prospective data to
describe the patient journey, to compare a baseline to a
postbiologic timeline, and even to answer the question of
who develops severe asthma.Conclusions
This study provides the first description, to our
knowledge, of an international population with
managed severe asthma, and identified differences in
demographic and clinical characteristics across
country and health-care systems. Initial country-
specific biomarker profiles have been identified.
Whether inter-counter differences are related to
underlying epidemiological factors, environmental
factors, phenotypes, asthma management systems,
treatment access, and/or cultural factors requires
further study. Prospective data collection for the ISAR
registry began in 2018 in Italy, the United States,
South Korea, and the United Kingdom. Prospective
data collection will ensure better standardization of
data fields, facilitating more accurate cross-country
comparisons and reducing any data incongruence in
upcoming ISAR data sets.801
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